In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: A comparison with losartan

American Journal of Hypertension

Volumn 13, Issue 9, 2000, Pages 1005-1013

  Fabiani, Maurice E ^a   Dinh, Diem T ^a   Nassis, Labrini ^a   Casley, David J ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin antagonists; Angiotensin receptors; AT1 receptor antagonists; AT1 receptors; Candesartan; Losartan

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN RECEPTOR; CANDESARTAN; CANDESARTAN HEXETIL; IODINE 125; LOSARTAN; RENIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD PRESSURE REGULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SELECTIVITY; KIDNEY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; IMIDAZOLES; KIDNEY; LOSARTAN; MALE; MEMBRANES; OSMOLAR CONCENTRATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN; TETRAZOLES;

EID: 0033811741     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)00286-7     Document Type: Article

References (35)

1. Biochemistry and pharmacology of the renin-angiotensin system
2. Molecular insights into angiotensin II type 1 and type 2 receptors: Expression, signaling and physiological function and clinical application of its antagonists
3. Angiotensin receptor subtypes: Novel targets for cardiovascular therapy
4. 2 receptors
5. 2 receptor
6. Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues
7. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues
8. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
9. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors
10. Adverse effects of the angiotensin-converting enzyme inhibitors
11. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management
12. Mechanisms of angiotensin II formation in humans
13. Dual pathway for angiotensin II formation in human internal mammary arteries
14. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases
15. Candesartan cilexetil: A new, long acting, effective angiotensin II type 1 receptor blocker
16. 1 receptor blocker: Pharmacology, antihypertensive efficacy, renal function, and renoprotection
17. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
18. Candesartan cilexetil: A review of its preclinical pharmacology
19. 1 receptor
20. Angiotensin receptor antagonists: Focus on losartan
21. 1 angiotensin II receptors in rat kidney
22. 1 angiotensin II receptors in rat brain, kidney and adrenals demonstrated by in vitro autoradiography
23. Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats
24. Evaluation of renin and angiotensin assays and their clinical applications
25. Measurement of angiotensin converting enzyme inhibitors in serum by radioinhibitor binding displacement assay
26. 2-receptors in rat kidney
27. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
28. Application of Bradford's protein assay to adrenal gland subcellular fractions
29. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
30. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-ca rboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-ca rboxylate (TCV-116)
31. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116
32. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy) ethyl2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats
33. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension
34. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
35. Comparison of angiotensin II receptor blockers: Impact of missed doses of candesartan cilexetil and losartan in systemic hypertension